CytoBioScience, Inc. acquired WestMountain Company in a reverse merger transaction on March 19, 2018. Pursuant to terms of agreement, all outstanding shares of capital stock of CytoBioscience were cancelled and exchanged for the issuance of 42.5 million shares of common stock of WestMountain. In addition, warrants to purchase 2 million shares of common stock of WestMountain were issued in exchange for all outstanding warrants of CytoBioscience, which were cancelled. Also, all of the newly issued shares will be subject to a lock-up agreement which prohibits sales for a period of at least two years. In a related transaction, CytoBioScience will commence an equity offering in an amount of $1.5 million. The offering will include shares of CytoBioScience’s common stock which will convert to up to 2 million shares of Parent Common Stock and warrant which will be converted on a one-for-one basis to warrants for WestMountain’s common stock exercisable contingent upon the authorization of additional shares. The shares of WestMountain common stock issued to CytoBioscience's shareholders in the transaction constitute approximately 74% of the issued and outstanding shares of WestMountain's common stock as of and immediately after the consummation of the transaction. Post transaction, WestMountain Company will change its name to CytoBioScience, Inc. In connection with the transaction, Brian L. Klemsz resigned as an officer of WestMountain, and James Garvin, Chief Executive Officer of CytoBioscience, became Chief Executive Officer of WestMountain, Thomas Knott as the Chief Science Officer of WestMountain, and Henry Bourg became Chief Financial Officer of WestMountain. The Directors of the WestMountain will seek shareholder approval to change the name of WestMountain to CytoBioscience, Inc. The transaction is subject to the consummation of equity offering. Gregory S. Curran of Maynard Cooper & Gale, P.C. acted as the legal advisor to CytoBioScience whereas Ken Bart of Bart and Associates, LLC acted as the legal advisor to WestMountain on the transaction. CytoBioScience, Inc. completed the acquisition of WestMountain Company in a reverse merger transaction on March 19, 2018.